Open-Label Phase III Clinical Trial to Evaluate the Safety of 0.03% DSC127 Gel in Chronic Use for Treating Diabetic Foot Ulcers ("DFU")

Trial Profile

Open-Label Phase III Clinical Trial to Evaluate the Safety of 0.03% DSC127 Gel in Chronic Use for Treating Diabetic Foot Ulcers ("DFU")

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Aclerastide (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions; Registrational
  • Acronyms STRIDE-5
  • Sponsors Derma Sciences
  • Most Recent Events

    • 12 Nov 2015 According to a Derma Sciences media release, this study has been terminated based on futility determinations conducted by the Data Monitoring Committee (DMC) for the planned, pre-specified interim analyses regarding the primary efficacy endpoint.
    • 12 Nov 2015 Status changed from active, no longer recruiting to discontinued according to a Derma Sciences media release.
    • 02 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top